Cosmo Pharmaceuticals

Dublin, Ireland Founded: 1996 • Age: 30 yrs
Therapeutics for gastrointestinal diseases are developed and provided.
Annual revenue $280.5M Latest available
Total funding - 1 rounds
Employees 321 Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals is a company based in Dublin (Ireland) founded in 1996 by Mauro Ajani. The company has 321 employees as of December 31, 2024. Cosmo Pharmaceuticals has completed 2 acquisitions, including BioXell and Cassiopea. Cosmo Pharmaceuticals operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, RedHill Biopharma, Alcresta and Norgine, among others.

  • Headquarter Dublin, Ireland
  • Employees 321 as on 31 Dec, 2024
  • Founders Mauro Ajani
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Cosmo Pharmaceuticals Nv
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $280.52 M (USD)
    181.94
    as on Dec 31, 2024
  • Net Profit
    $140.09 M (USD)
    0
    as on Dec 31, 2024
  • EBITDA
    $165.61 M (USD)
    1816.78
    as on Dec 31, 2024
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    321

    as on Dec 31, 2024

  • Investments & Acquisitions
    BioXell

    & 1 more

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Cosmo Pharmaceuticals

Cosmo Pharmaceuticals is a publicly listed company on the SIX with ticker symbol COPN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: SIX · Ticker: COPN · Sector: Health technology · Switzerland

People of Cosmo Pharmaceuticals

Headcount 200-500
Employee Profiles 15
Board Members and Advisors 4
Employee Profiles
People
Mara Gerloni
SVP of Preclinical Operations
People
Stefania Pagani
Deputy Chief Scientific Officer
People
Marco Lecchi
Chief Operating Officer
People
Roberto Villa
Chief Manufacturing Officer

Unlock access to complete

Board Members and Advisors
people
Maria Grazia Roncarolo
Non-Executive Director
people
Mauro Severino Ajani
Non-Executive Director, Chairman
people
Kevin Donovan
Non-Executive Director
people
David W. Maris
Non-Executive Director

Unlock access to complete

Funding Insights of Cosmo Pharmaceuticals

Investors in Cosmo Pharmaceuticals

Cosmo Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Invision.

All
Venture Fund
Investor Description Founded Year Domain Location
Invision is engaged in providing investment and succession solutions for mid-sized companies.
Locked Locked Locked
Premium access

Investor details for Cosmo Pharmaceuticals

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cosmo Pharmaceuticals

Cosmo Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include BioXell and Cassiopea.

Investments
Premium access

Investment portfolio details for Cosmo Pharmaceuticals

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Clinical-stage pharma company focused on Italian dermatology treatments.
Locked Locked 2009 Locked
Italian, clinical stage biopharma developing small molecule and antibody therapeutics for chronic inflammatory and autoimmune diseases
Locked Locked 2002 Locked
Premium access

Complete acquisition details for Cosmo Pharmaceuticals

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Cosmo Pharmaceuticals

Premium access

Detailed financials for Cosmo Pharmaceuticals

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cosmo Pharmaceuticals Comparisons

Cosmo Pharmaceuticals Primary company
Description
Therapeutics for gastrointestinal diseases are developed and...
Location
Dublin, Ireland
Founded Year
1996
Annual Revenue
$280.52 M (USD)
Net Profit
$140.09 M (USD)
EBITDA
$165.61 M (USD)
Employees
321
As of 2024
Premium access

Peer comparison for Cosmo Pharmaceuticals

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Cosmo Pharmaceuticals

Cosmo Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, RedHill Biopharma, Alcresta and Norgine, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
Locked Locked Locked
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
Locked Locked Locked
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
Locked Locked Locked
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
Locked Locked Locked
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed.
Premium access

Detailed competitors of Cosmo Pharmaceuticals

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cosmo Pharmaceuticals

Premium access

Complete news archive for Cosmo Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cosmo Pharmaceuticals

Cosmo Pharmaceuticals was founded in 1996 and raised its 1st funding round 12 years after it was founded.

Cosmo Pharmaceuticals is headquartered in Dublin, Ireland.

As of Dec 31, 2024, the latest employee count at Cosmo Pharmaceuticals is 321.

Annual revenue of Cosmo Pharmaceuticals is $280.52M as on Dec 31, 2024.

Cosmo Pharmaceuticals was founded in 1996 in Dublin, Ireland, within the pharmaceuticals sector. Therapeutics targeting gastrointestinal diseases are developed, including Aemcolo for inflammatory bowel conditions, Byfavo for sedation in colonoscopy procedures, MethyleneBlue MMX for lesion detection during colonoscopies, and CB-03-10 for solid tumors. Additionally, GI Genius AI-enhanced software is provided to support endoscopy processes.

Cosmo Pharmaceuticals's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.

Yes, Cosmo Pharmaceuticals is publicly traded on SIX under the ticker symbol COPN.

Cosmo Pharmaceuticals has made 2 acquisitions, including BioXell, and Cassiopea.

Cosmo Pharmaceuticals has 1 investor. Key investors include Invision.

The ticker symbol of Cosmo Pharmaceuticals is COPN on SIX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available